SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Benedetta Conte(Ospedale Policlinico San Martino), Lucia Del Mastro(Ospedale Policlinico San Martino), Francesca Poggio(Ospedale Policlinico San Martino), Francesco Schettini(Target (United States)), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Fabio Puglisi(University of Udine), Bárbara Cardinali(Ospedale Policlinico San Martino), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Daniele Generali(University of Trieste), Claudia Bighin(Azienda Ospedaliera S.Maria), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Martina Serra(University of Genoa), Filippo Montemurro(Roche (Switzerland)), Mauro Porpiglia(Ospedale Sant'Anna), Gianluigi Lunardi(Ospedale Sacro Cuore Don Calabria), Rosario Notaro, Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), Patrizia Piccioli(Ospedale Policlinico San Martino), Giovanni Scognamiglio(Ospedale Valduce), Alessandra Fabi(Agostino Gemelli University Polyclinic), Giancarlo Bisagni, Sonia Lastraioli(Ospedale Policlinico San Martino), Maura Rossi(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Maria De Angioletti(Joint Research Centre), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Antonio Pazzola(Azienda Ospedaliero Universitaria di Sassari), Riccardo Ponzone(Candiolo Cancer Institute), Anna Turletti(Ospedale Martini), Giovanni Sanna(University of Sassari), Sabino De Placido, Luca Boni(Ospedale Policlinico San Martino), Matteo Lambertini(Ospedale Policlinico San Martino), Antonio Durando(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Aleix Prat(Hospital Clínic de Barcelona), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna)
Cited by 7
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k